Hyderabad-based Indian Immunologicals Limited (IIL), a vaccine manufacturer has announced receipt of approval from Drugs Controller General of India (DCGI) and State Drug Control Administration for manufacture of Measles-Rubella (MR) Vaccine.
This is the outcome of the Indo-Vietnam partnership, where IIL partnered with the Center for Research and Production of Vaccines and Biologicals, also called Polyvac, Vietnam.
Under an exclusive agreement, Polyvac, Vietnam will supply the Measles vaccine component to IIL. Rubella Vaccine components will be produced by IIL to manufacture a combined MR vaccine. This Live Attenuated MR vaccine adds to the list of several other vaccines that IIL supplies to Universal Immunization Programme (UIP) of India. This vaccine has been proven through extensive human clinical trials to be immunogenic and safe for people of 9 months to 49 years.
Dr K Anand Kumar, Managing Director, IIL said, “We have successfully completed all phases of Product development to the satisfaction of the regulatory authorities in India. Measles-Rubella (MR) vaccine is listed in the UIP of India and is an important vaccine for our country. IIL’s collaborative effort will help in the immunization of several million children against Measles and Rubella and thereby saving lives’ ‘.
